CERo Financial Statements From 2010 to 2026

CERO Stock   0.04  0  6.25%   
CERo Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CERo Therapeutics' valuation are provided below:
Gross Profit
-500 K
Market Capitalization
949.6 K
Earnings Share
(3.01)
We have found one hundred ten available fundamental signals for CERo Therapeutics Holdings, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate CERo Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself for few more years.
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 118.3 K, Interest Income of 118.3 K or Depreciation And Amortization of 961.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with CERo Stock
Check out the analysis of CERo Therapeutics Correlation against competitors.

CERo Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.3 M5.6 M130.9 M
Slightly volatile
Short and Long Term Debt Total1.5 M1.4 M2.9 M
Slightly volatile
Total Current Liabilities8.7 M6.7 M3.5 M
Slightly volatile
Property Plant And Equipment Net2.8 M1.8 M4.1 M
Slightly volatile
Accounts Payable2.7 M5.2 MM
Slightly volatile
Cash2.8 MM3.9 M
Pretty Stable
Non Current Assets Total2.1 M2.2 M127 M
Slightly volatile
Cash And Short Term Investments2.8 MM3.9 M
Pretty Stable
Common Stock Shares Outstanding145.9 K138.9 K29.9 K
Slightly volatile
Liabilities And Stockholders Equity5.3 M5.6 M130.9 M
Slightly volatile
Non Current Liabilities Total597.7 K629.2 K8.1 M
Slightly volatile
Capital Lease Obligations2.1 M1.4 M3.2 M
Slightly volatile
Other Current Assets341.9 K445 K289.3 K
Slightly volatile
Total Liabilities8.9 M9.3 M13.2 M
Slightly volatile
Property Plant And Equipment Gross3.9 M3.6 MM
Slightly volatile
Total Current Assets3.2 M3.3 M4.2 M
Pretty Stable
Capital Stock3.8 M3.7 M628.1 K
Slightly volatile
Short Term DebtMM713 K
Slightly volatile
Common Stock207218126.8 M
Slightly volatile
Short Term Investments6.7 M7.6 M8.3 M
Slightly volatile
Other Stockholder Equity79.5 M75.7 M13.9 M
Slightly volatile
Short and Long Term Debt479.8 K539.7 K589.1 K
Slightly volatile

CERo Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income118.3 K124.5 K735.4 K
Slightly volatile
Interest Income118.3 K124.5 K735.4 K
Slightly volatile
Depreciation And Amortization961.4 KM876.8 K
Pretty Stable
Selling General Administrative10.8 M10.3 M3.7 M
Slightly volatile
Selling And Marketing Expenses2.1 M3.3 M2.3 M
Pretty Stable
Other Operating Expenses18.5 M17.6 M3.6 M
Slightly volatile
Research Development6.1 M5.7 M8.4 M
Slightly volatile
Total Operating Expenses18.5 M17.6 M3.7 M
Slightly volatile
Reconciled Depreciation1.1 M1.3 M852.4 K
Slightly volatile
Cost Of Revenue1.3 M1.3 M1.1 M
Slightly volatile

CERo Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation172.5 K87.2 K252.2 K
Slightly volatile
Begin Period Cash Flow8.9 M6.1 M22.8 M
Slightly volatile
Depreciation1.1 M1.3 M854.7 K
Slightly volatile
Capital Expenditures0.860.9473.2 K
Slightly volatile
End Period Cash Flow1.4 M1.4 M3.6 M
Pretty Stable
Net Borrowings484.2 K544.7 K594.5 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables667 K750.4 K819.1 K
Slightly volatile
Capex To Depreciation0.00.00.626
Slightly volatile
Payables Turnover0.320.30.3119
Slightly volatile
Cash Per Share30.0931.67461
Pretty Stable
Days Payables OutstandingK1.3 K1.2 K
Pretty Stable
Income Quality0.330.630.1959
Slightly volatile
Net Debt To EBITDA0.290.3140.0274
Pretty Stable
Current Ratio0.550.589.9959
Slightly volatile
Capex Per Share4.0E-45.0E-464.3598
Slightly volatile
Interest Debt Per Share14.2515.0366
Slightly volatile
Debt To Assets0.120.230.0684
Slightly volatile
Days Of Payables OutstandingK1.3 K1.2 K
Pretty Stable
Ebt Per Ebit0.650.580.8591
Slightly volatile
Quick Ratio0.550.589.9959
Slightly volatile
Net Income Per E B T1.091.151.4335
Pretty Stable
Cash Ratio0.490.528.0918
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.941.881.8395
Slightly volatile
Debt Ratio0.120.230.0684
Slightly volatile

CERo Fundamental Market Drivers

About CERo Therapeutics Financial Statements

CERo Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how CERo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue23.1 K24.3 K
Cost Of Revenue1.3 M1.3 M

Pair Trading with CERo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CERo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CERo Stock

  0.76DWTX Dogwood TherapeuticsPairCorr
  0.76EDIT Editas MedicinePairCorr

Moving against CERo Stock

  0.6263E ONWARD MEDICAL BVPairCorr
  0.59IMMP Immutep Ltd ADRPairCorr
  0.55DSGN Design TherapeuticsPairCorr
  0.52ENGN enGene Holdings CommonPairCorr
  0.35KYTX Kyverna TherapeuticsPairCorr
The ability to find closely correlated positions to CERo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CERo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CERo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CERo Therapeutics Holdings to buy it.
The correlation of CERo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CERo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CERo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CERo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CERo Therapeutics is a strong investment it is important to analyze CERo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CERo Therapeutics' future performance. For an informed investment choice regarding CERo Stock, refer to the following important reports:
Check out the analysis of CERo Therapeutics Correlation against competitors.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Will Biotechnology sector continue expanding? Could CERo diversify its offerings? Factors like these will boost the valuation of CERo Therapeutics. Projected growth potential of CERo fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CERo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(3.01)
Return On Assets
(2.10)
Understanding CERo Therapeutics requires distinguishing between market price and book value, where the latter reflects CERo's accounting equity. The concept of intrinsic value - what CERo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CERo Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between CERo Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CERo Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CERo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.